research Identification of Differentially Expressed miRNAs in Alopecia Areata That Target Immune-Regulatory Pathways
Certain microRNAs may help treat alopecia areata by targeting immune pathways.
Search
for
Sort by
Research
120-150 / 1000+ results
research Rapidly Progressive Alopecia Areata Totalis in a COVID-19 Patient, Unresponsive to Tofacitinib
A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research Response to Tofacitinib Therapy of Eyebrows and Eyelashes in Alopecia Areata
Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
research Recalcitrant Alopecia Areata Responsive to Leflunomide and Anthralin—Potentially Undiscovered JAK/STAT Inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata
New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
research Balance of Tofacitinib Efficacy and Disease Flare in the Treatment of Alopecia Universalis: A Case Report and Review of the Literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Genes and Immune Response in Alopecia Areata: Review of the Alopecia Areata Research Summit First Day Proceedings
Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.
research Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Tofacitinib for the Treatment of Three Immune-Mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Apremilast and Tofacitinib Exert Differential Effects in the Humanized Mouse Model of Alopecia Areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research What’s New in Hair Loss
New treatments for hair loss show promise, but require more research on long-term effects and proper dosing.
research Biologics in the Management of Childhood Atopic Dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research TREM2+ Macrophages Inhibit Hair Growth by Producing Oncostatin M
Certain immune cells in the skin can stop hair from growing.
research Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
research Good Efficacy Achieved by Baricitinib in the Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis with Alopecia Areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research Alopecia Areata: Medical Treatments
Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research Topical Curcumin Promotes Induction of the Murine Hair Cycle
Curcumin applied to the skin can start hair growth in mice.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients With APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research AIRE Deficiency Leads to the Development of Alopecia Areata-Like Lesions in Mice
AIRE deficiency causes hair loss similar to alopecia areata in mice.
research Hair Regrowth in a Patient With Central Centrifugal Cicatricial Alopecia After a 2-Month Trial of Baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Novel Potential Therapeutic Targets of Alopecia Areata
New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.